Role of Treatment with Remdesivir on the Early Readmission of Patients Affected by Nosocomial Coronavirus Disease 2019

Background: The patients affected by hospital-acquired coronavirus disease 2019 (HA-COVID-19) who were readmitted in hospital within 60 days had worse prognosis and mortality. In this study the aim was the assessment of early readmission rate in HA-COVID-19 and the role of remdesivir treatment. Materials and Methods: This observational retrospective study included patients with HA-COVID-19 hospitalized in different wards between Jan 2021 and Mar 2022. Early readmission rate was determined. A multivariate logistic regression was made to determine the predictive factors for re-hospitalization. Results: A total of 190 patients with a confirmed diagnosis of HA-COVID-19 were included. Early readmission was documented in 22 patients (11.6%) with a consequent mortality rate of 22.7%. In multivariate analysis, the following factors were predictive of readmission: chronic pulmonary disease (odds ratio [OR], 3.187; 95% confidence interval [CI], 2.145-11.228; P<0.001), hospitalization time >= 11 days (OR, 3.556; 95% CI, 1.442-8.417; P=0.008), intensive care unit support (OR, 7.449; 95% CI, 3.901-14.782; P<0.001), and remdesivir use (OR, 0.729; 95% CI, 0.512-0.884; P=0.001). Conclusion: Readmission cumulative rate was about one tenth with higher mortality. The remdesivir use in the first hospitalization leads to significant reduction in the odds of readmission.